Rigel Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
171.80 |
204.42 |
233.39 |
255.27 |
274.02 |
298.65 |
| Przychód Δ r/r |
0.00% |
18.99% |
14.17% |
9.37% |
7.34% |
8.99% |
| Przychód (min) |
158.52 |
199.93 |
221.77 |
252.80 |
252.84 |
275.57 |
| Przychód (max) |
186.53 |
207.81 |
260.70 |
257.74 |
297.53 |
324.27 |
| EBITDA (średnia) |
-26.28 |
-31.27 |
-35.70 |
-39.04 |
-41.91 |
-45.68 |
| EBIT (średnia) |
-27.84 |
-33.13 |
-37.83 |
-41.37 |
-44.41 |
-48.40 |
| EBIT % |
-16.21% |
-16.21% |
-16.21% |
-16.21% |
-16.21% |
-16.21% |
| Zysk netto (średni) |
6.57 |
66.44 |
36.21 |
35.89 |
18.66 |
22.82 |
| Zysk netto % |
3.82% |
32.50% |
15.52% |
14.06% |
6.81% |
7.64% |
| EPS (średnia) |
0.39 |
3.76 |
1.61 |
1.49 |
1.05 |
1.29 |
| Liczba analityków (Przychody) |
2 |
5 |
6 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
4 |
5 |
5 |
4 |
3 |
2 |
| symbol |
RIGL |
RIGL |
RIGL |
RIGL |
RIGL |
RIGL |